Fig. 3From: The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trialKaplan–Meier curves showing the duration of response (A), progression-free survival (B), and overall survival (C) in the ITT cohort (n = 64)Back to article page